409A Valuation: Process, Safe Harbor & Checklist

A 409A valuation is a determination of the fair market value of a private company's common stock. Its most familiar use is supporting the exercise price on a stock-option grant: a nondiscounted option generally needs an exercise price at least equal to the underlying stock's fair market value on the grant date.

The report is not the company's fundraising valuation, a promise about an employee's eventual payout, or a license to keep granting options for a year regardless of what changes. It is dated evidence. Management and the board still need to confirm that the report uses the right capital structure, reflects all material information, and supports the actual grant date.

The practical test is simple: do we have a reasonable, current basis for the common-stock value used on this grant? The rest of the process exists to make the answer defensible.

This article is educational and focuses on the common US private-company option use case. Section 409A covers a wider field of nonqualified deferred compensation, and individual awards can differ. Use qualified legal, tax, accounting, and valuation advisers for the company's facts and documents.

What is a 409A valuation?

Public-company shares have an observable trading price. Private-company common stock does not. A 409A valuation applies a reasoned valuation method to determine common-stock fair market value as of a specific date.

That per-share value can support the exercise, or strike, price on a stock-option grant. If the supported FMV is $0.80 per common share, a company seeking the usual nondiscounted-option exclusion would generally grant the option with an exercise price of at least $0.80—not below it.

Four distinctions prevent most misunderstandings:

Common stock is not preferred stock. Employees typically receive options over common stock. Venture investors often buy preferred stock with liquidation preferences and other negotiated rights.
FMV is not enterprise value. The appraiser first estimates the business or equity value, then allocates that value across a capital structure before arriving at common-stock FMV per share.
The valuation date is not the grant date by default. The report may support a later grant only if it remains a reasonable view at that later date.
A strike price is not an offer value. It tells an employee what it costs to exercise each option. It does not reveal percentage ownership, dilution, preferences, taxes, or the probability and timing of liquidity.

The US Treasury regulations frame private-stock FMV as the reasonable application of a reasonable valuation method. They direct the analysis toward facts such as assets, anticipated cash flows, comparable interests, arm's-length transactions, control factors, and marketability. The company cannot select a convenient number while ignoring information material to value. The IRS-hosted final regulations are the primary reference for these rules.

When does a private company need a new 409A valuation?

The company needs a supported FMV before it fixes the exercise price for a relevant private-company option grant. In practice, that means establishing a valuation before the first grants and refreshing the work when age or later facts make the current conclusion unreasonable.

The 12-month limit is an outside boundary

An independent appraisal can qualify for a presumption of reasonableness when its valuation date is no more than 12 months before the transaction to which it is applied. Separately, the regulations say a previously calculated value is not reasonable when it is more than 12 months old.

That does not make every valuation automatically usable for a full year. The same rule says a prior value is not reasonable if it fails to reflect later information that may materially affect the company.

New information can make the current value stale sooner

Common reassessment triggers include:

a priced equity financing, a meaningful secondary transaction, or a change in the rights attached to a security;
a credible acquisition process, change-of-control development, IPO preparation, or other shift in the probability or timing of liquidity;
performance that is materially above or below the forecast used by the appraiser;
a major customer win or loss, product approval, partnership, litigation resolution, patent issuance, or other company-specific event;
a recapitalization, option-pool change, SAFE or note conversion, or other change that makes the report's fully diluted share count or allocation model wrong; or
a broad market or comparable-company movement significant enough to contradict the selected assumptions.

A financing is an obvious prompt to reassess, but the legal test is not a list of labels. It is whether information available by the proposed grant date may materially affect value. J.P. Morgan's founder overview gives useful examples of financing, milestones, capitalization changes, and transaction developments.

Can the company use its current value?

Check	If yes	Control response
Is the valuation date more than 12 months before the proposed grant?	The prior value is not reasonable for this use	Obtain an updated valuation before fixing the exercise price
Has material information arisen since the report's information cutoff?	The old conclusion may no longer be reasonable	Pause grants, send the facts to counsel and the appraiser, and document whether a refresh is needed
Do the report's cap table, security rights, forecasts, or recent transactions differ from current records?	The model may answer the wrong facts	Correct the inputs and refresh or revise the report before approval
Are none of those issues present?	The report may still support the grant	Confirm the grant date, board action, and exercise price; retain the evidence

When the answer is uncertain, pausing a grant batch is usually cheaper than repairing discounted or poorly supported grants later.

What 409A safe harbor actually means

“Safe harbor” is useful shorthand, but it is often overstated. The baseline rule is still a reasonable application of a reasonable valuation method based on the facts as of the valuation date. The regulations then identify methods that receive a presumption of reasonableness. The IRS may rebut that presumption by showing the method or its application was grossly unreasonable.

The three regulatory presumptions are:

Independent appraisal. A qualifying independent appraisal of the relevant stock class, dated no more than 12 months before the relevant transaction. This is the common startup route because it separates the valuation judgment from management's incentive to set a low strike price.
Generally applicable formula. A qualifying formula-based value used consistently for specified compensatory and noncompensatory transfers. The consistency conditions make this a poor fit for many venture-backed companies.
Illiquid startup stock. A good-faith written valuation by a qualified person for a qualifying young, illiquid corporation, subject to detailed limits—including limits tied to anticipated change-of-control events and public offerings.

The third route is not a general founder self-certification. The corporation must reasonably determine that the person performing the work is qualified based on significant knowledge, experience, education, or training; the regulation says significant experience generally means at least five years of relevant work. The company and stock must also satisfy the other conditions.

An independent report does not cure bad inputs. If management omits a signed term sheet, uses an obsolete cap table, or supplies a forecast it already knows is no longer credible, the independence of the appraiser does not make the application reasonable. Safe harbor changes the evidentiary position; it does not remove the need for honest, current information and competent review.

How a 409A valuation is calculated

The calculation is easier to understand as three linked decisions. It is not a single multiple applied to the last financing announcement.

1. Estimate the company's value

An appraiser may use one or more approaches:

Market approach: compare the company with public companies, relevant transactions, or a recent arm's-length financing. After a financing, a backsolve can use the preferred-stock transaction to infer the company's value while respecting the security's terms.
Income approach: forecast cash flows and discount them for timing and risk. This becomes more useful when the company has a credible, supportable operating forecast.
Asset approach: estimate the value of assets less liabilities. This can matter for very early, distressed, holding, or asset-heavy businesses, but it may fail to capture a growth company's intangible value.

The regulations do not prescribe one startup formula. They require the method and its application to be reasonable for the facts. An appraiser may reconcile several indications rather than mechanically select the highest or lowest result.

2. Allocate value across the capital structure

A venture-backed cap table may include common stock, several preferred series, options, warrants, SAFEs, and convertible notes. Those claims do not all have identical economics.

Allocation methods such as the option pricing method (OPM), probability-weighted expected return method (PWERM), or a hybrid can reflect liquidation preferences, conversion rights, participation, seniority, and different exit paths. A recent preferred financing can be a strong input without making the preferred price the common-stock price.

This step is why the cap table and the charter belong in the valuation packet. A missing preference or the wrong fully diluted share count can move the concluded FMV per common share even if the headline company value is unchanged.

After allocating value to common stock, the appraiser divides by the appropriate share count and considers facts such as lack of marketability. Private common stock cannot normally be sold as freely as a public share, and an employee's security lacks many investor preferences.

There is no universal discount. Company stage, expected liquidity, transfer restrictions, volatility, secondary activity, and the selected allocation method all matter. Treating a competitor's percentage range as a rule would turn professional judgment into false precision.

Why the 409A price differs from the funding-round price

Assume a startup sells Series A preferred stock for $4.00 per share. A press release may use that preferred price to describe the financing valuation. The option pool, however, covers common stock.

The two securities can sit in the same company and still carry different values:

Preferred financing share	Common share underlying an employee option
May have a liquidation preference and senior claim on exit proceeds	Typically sits behind preferred claims in a downside exit
May have anti-dilution, protective, information, participation, or negotiated conversion rights	Usually lacks those investor-specific rights
Price is established in a negotiated financing for that security	FMV is estimated for common stock as of the valuation date
Investor may have contractual access, governance, and information	Employee commonly holds an illiquid option and later common stock

The appraiser can use the $4.00 transaction as evidence, model the rights and exit outcomes, allocate the company's value among securities, and consider marketability before concluding common-stock FMV. The final answer might be below $4.00, but the facts do not support inventing a fixed percentage discount.

Suppose the finished report concludes common-stock FMV of $1.10 per share and the board accepts the report. A new nondiscounted option grant could use an exercise price of $1.10 or more. The board should not substitute $4.00 merely because it was the financing price, and it should not push the price below $1.10 because a lower strike price looks more attractive to a hire.

This distinction also explains why pre-money valuation and post-money valuation are not substitutes for a 409A analysis. They describe a financing transaction or ownership arithmetic, not the FMV of common stock for a specific grant date.

The 409A operating workflow

A defensible process is a chain of evidence. If a link is missing, the board may approve a polished report that no longer describes the company.

1. Identify the trigger and proposed grant date

People operations or legal should flag an upcoming grant batch. Finance and counsel compare the proposed grant date with the valuation date and later company events.

2. Pause grants when the current support may be stale

Do not backdate a grant or assume the old FMV survives a financing. Escalate new facts before the board fixes the exercise price.

3. Assemble the valuation packet

Input	Typical owner	Why it matters
Current charter and amendments	Legal/counsel	Defines share classes and economic rights
Current fully diluted cap table	Legal/finance	Establishes outstanding securities, options and allocation denominator
Recent financing, SAFE, note and secondary documents	Legal/finance	Supplies arm's-length evidence and capital-structure changes
Historical financials, cash and debt	Finance	Anchors current condition and runway
Board-approved forecast and operating plan	Finance/management	Supports income and market assumptions
Comparable companies and transaction context	Management/appraiser	Tests market approach inputs
Material events since the prior valuation	Management/counsel	Prevents a stale information cutoff
Expected grant batch and timing	People ops/legal	Connects the valuation to the transaction it supports
IPO, M&A or liquidity expectations	Board/management/counsel	Affects method, scenarios and startup-presumption eligibility

4. Resolve questions before the draft is final

Management should explain the business model, forecast, milestones, risks, financing terms, comparables, and any difference between board materials and the valuation packet. An unexplained inconsistency is a review item, not an invitation to choose the friendlier document.

5. Review and approve

Finance checks the figures and cap table. Counsel checks award scope, valuation timing, corporate approvals, and option documents. Management confirms the information cutoff and business facts. The board reviews the concluded FMV and approves the grant action through the company's proper process.

6. Grant, retain, and monitor

Retain the report, data supplied, questions and responses, approval records, grant list, grant date, and exercise price. Then make new financing, transaction, forecast, legal, and capital-structure developments part of an ongoing refresh control—not an annual calendar reminder alone.

The output is not just a PDF. It is a traceable line from current company facts to common-stock FMV to a properly approved grant.

What to review in the report—and the provider

The board does not need to rebuild the model, but it should understand what changed and why. Management can use the following questions before accepting the final report.

Report review checklist

Valuation date and cutoff: What date does the conclusion cover? Which later events were considered, and which were not?
Capital structure: Does the model match the current charter and fully diluted cap table, including options, warrants, SAFEs, notes, and recent conversions?
Transaction evidence: Does it include the latest financing or secondary activity and the actual rights of the securities sold?
Method selection: Why do the market, income, asset, backsolve, OPM, PWERM, or hybrid methods fit this company at this stage?
Forecasts and comparables: Are they the same facts management and the board currently use? Are adjustments explained?
Equity allocation: Are liquidation preferences, conversion rights, participation, seniority, and exit scenarios modeled correctly? The liquidation preference is an economic input, not boilerplate.
Marketability: Is the DLOM analysis specific to this security and expected liquidity rather than copied from a generic range?
FMV per share: Does the final common-share count reconcile to the cap table? Can the board trace the conclusion from company value through allocation to per-share FMV?
Contradictory facts: Has anything happened since the data was delivered that would change a reasonable person's conclusion?

Stop and resolve an unexplained mismatch. “The appraiser signed it” is not a response to an obsolete forecast or missing financing document.

Provider selection checklist

A useful selection process asks:

Who performs and signs the valuation, and what relevant sector, stage, and capital-structure experience do they have?
Is the work an independent appraisal, and are any commercial relationships or conflicts disclosed?
What does the scope include: management call, draft review, revisions, board questions, audit support, and transaction support?
How will the provider treat recent financings, complex preferences, secondary sales, SAFEs, and potential liquidity scenarios?
What inputs, assumptions, model exhibits, and conclusion pages will the report show?
How are company data secured, retained, and deleted?
What happens if an auditor, tax adviser, acquirer, or regulator asks questions later?

Price and turnaround matter, but they are not substitutes for competent analysis, documented assumptions, and support when the work is reviewed.

What founders, VC teams, and employees should do with the number

The same FMV conclusion supports different decisions. Each audience needs a different checklist.

Founder or operator: control the grant

Confirm the current-value decision, deliver complete inputs, resolve draft questions, obtain proper approval, and keep the report tied to the exact grant list. Never promise a candidate that a low strike price guarantees upside. The company controls the quality of the process, not the future market.

VC analyst or associate: test the evidence

During portfolio support, financing, or venture capital due diligence, ask:

What is the latest valuation date, information cutoff, and provider?
Which options were granted after that date, at what exercise prices, and under which board approvals?
Did a financing, secondary, material forecast change, or transaction process occur before any of those grants?
Does the valuation cap table reconcile to the current fully diluted cap table and charter rights?
Are there exceptions, repricings, audit questions, or counsel notes that require follow-up?

The output should be a short exception memo: what was tested, what reconciled, what did not, who owns the answer, and whether grants or the transaction should pause. That is practical financial and legal-process work, not abstract valuation trivia.

These controls are common in investing and portfolio roles. Candidates building this skill can review the responsibilities in a venture capital analyst job description and browse open venture capital roles when they are ready to apply it.

Employee or candidate: do not mistake strike price for value

A 409A price answers one question: the supported FMV per common share used for the grant. To evaluate an option offer, also ask for:

the number of options and the current fully diluted share count, so you can estimate ownership percentage;
the latest preferred price and financing date, with the warning that preferred and common rights differ;
the 409A valuation date and whether a material event occurred after it;
vesting, cliff, expiration, post-termination exercise window, early-exercise rules, and change-of-control treatment;
the exercise cost and a qualified adviser's view of the tax consequences;
the liquidation preferences and other claims ahead of common stock; and
any realistic liquidity path, transfer restrictions, tender history, and expected dilution.

Even with every answer, a private-company option can end up worth nothing. Evaluate salary and other compensation on their own merits, and treat equity as a risky, illiquid claim rather than guaranteed cash.

What can happen if options are granted below FMV?

A stock option with an exercise price that can never be less than FMV on the grant date, and no additional deferral feature, is generally outside Section 409A's deferred-compensation treatment. A discounted option can fall on the other side of that line.

IRS guidance describes potential consequences for affected service providers that include current income inclusion, an additional 20% federal income tax on the amount required to be included, and a premium interest tax. The IRS discussion of discounted stock rights also describes employer reporting consequences. The exact amount and timing depend on the award, vesting, exercise, plan aggregation, tax year, and other facts.

The company can also face a repair project: grant review, valuation revisions, payroll and tax reporting, financial-statement work, transaction diligence, delayed grants, adviser cost, and difficult employee communication. Do not calculate or correct an individual case from a general article. Use the option documents and qualified tax and legal advisers.

Frequently asked questions

Is a 409A valuation the same as a startup valuation?

No. A financing valuation reflects a negotiated transaction, often in preferred stock. A 409A analysis determines common-stock FMV for a specific date and purpose after considering the capital structure and other relevant facts.

Is an independent appraiser always legally required?

The regulations require a reasonable valuation method; they also provide a presumption of reasonableness for a qualifying independent appraisal. Two narrower presumptions exist, but their conditions make an independent appraisal the common venture-backed startup process. Counsel should confirm the right approach.

Can a startup do its own 409A valuation?

Do not assume so. The illiquid-startup presumption has company, stock, transaction-timing, written-report, and appraiser-qualification conditions. A founder's preferred number is not a valuation method. Even outside a presumption, the company still needs a reasonable method reasonably applied to all material facts.

Does every funding event automatically require a refresh?

A financing commonly supplies material new information and changes the capital structure, so it should trigger an immediate reassessment. Whether a particular event requires new work depends on the facts and proposed grant date. Send the documents to counsel and the appraiser before further grants.

Is a 409A valuation valid for exactly 12 months?

No. More than 12 months is outside the regulatory limit for the prior value, but material later information can make it unreasonable sooner. Think “up to 12 months, only while the facts still support it,” not a one-year warranty.

Does a low 409A value mean an employee option is a good deal?

No. It lowers the exercise cost relative to a higher strike price, all else equal. It says nothing by itself about ownership percentage, dilution, preferences, taxes, liquidity, exit value, or the probability the common stock ever exceeds the exercise price.

The control that matters

Before approving an option grant, connect four records: current company facts, a reasonable common-stock FMV conclusion, the board's approval, and the grant ledger. Then monitor for information that breaks the connection.

A company that can trace that line is treating 409A as an operating control. A company that only remembers to order a PDF every 12 months is leaving the most important question unanswered.